EA200900404A1 - Новые гены, родственные гену глутаминилциклазы - Google Patents

Новые гены, родственные гену глутаминилциклазы

Info

Publication number
EA200900404A1
EA200900404A1 EA200900404A EA200900404A EA200900404A1 EA 200900404 A1 EA200900404 A1 EA 200900404A1 EA 200900404 A EA200900404 A EA 200900404A EA 200900404 A EA200900404 A EA 200900404A EA 200900404 A1 EA200900404 A1 EA 200900404A1
Authority
EA
Eurasian Patent Office
Prior art keywords
genes
isozymes
glutaminylciclase
glutaminyl
cyclase
Prior art date
Application number
EA200900404A
Other languages
English (en)
Other versions
EA016584B1 (ru
Inventor
Штефан Шиллинг
Хольгер Цинис
Йенс-Ульрих Рафельд
Ханс-Ульрих Демут
Original Assignee
Пробиодруг Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пробиодруг Аг filed Critical Пробиодруг Аг
Publication of EA200900404A1 publication Critical patent/EA200900404A1/ru
Publication of EA016584B1 publication Critical patent/EA016584B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)

Abstract

В заявке описаны новые белки, напоминающие глутаминилпептидциклотрансферазу (QPCTL), которые являются изозимами глутаминилциклазы (QC, К.Ф. 2.3.2.5), и выделенные нуклеиновые кислоты, кодирующие эти изозимы, которые все можно применять для выявления новых терапевтических агентов, измерения циклазной активности и для определения ингибирующей активности соединений в отношении этих изозимов глутаминилциклазы.
EA200900404A 2006-09-21 2007-09-21 Новые гены, родственные гену глутаминилциклазы EA016584B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84624406P 2006-09-21 2006-09-21
US94778007P 2007-07-03 2007-07-03
PCT/EP2007/060013 WO2008034891A2 (en) 2006-09-21 2007-09-21 Novel genes related to glutaminyl cyclase

Publications (2)

Publication Number Publication Date
EA200900404A1 true EA200900404A1 (ru) 2009-10-30
EA016584B1 EA016584B1 (ru) 2012-06-29

Family

ID=38779576

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900404A EA016584B1 (ru) 2006-09-21 2007-09-21 Новые гены, родственные гену глутаминилциклазы

Country Status (13)

Country Link
US (3) US20080249083A1 (ru)
EP (2) EP2581449B1 (ru)
JP (1) JP2010504088A (ru)
KR (1) KR101432848B1 (ru)
AU (1) AU2007298929B2 (ru)
BR (1) BRPI0718507A2 (ru)
CA (1) CA2663635A1 (ru)
EA (1) EA016584B1 (ru)
HK (1) HK1136603A1 (ru)
IL (2) IL197090A (ru)
MX (1) MX2009003090A (ru)
NZ (2) NZ590631A (ru)
WO (1) WO2008034891A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381537B2 (en) * 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US9277737B2 (en) * 2006-09-21 2016-03-08 Probiodrug Ag Mouse models carrying a knock-out mutation of the QPCTL-gene
US8889709B2 (en) 2006-09-21 2014-11-18 Probiodrug Ag Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
EP2089383B1 (en) * 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US8420684B2 (en) * 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2086960B1 (en) * 2006-11-09 2014-03-05 Probiodrug AG Novel inhibitors of glutaminyl cyclase
DK2091948T3 (da) * 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
AU2008206936B2 (en) * 2007-01-19 2013-03-14 Probiodrug Ag In vivo screening models for treatment of Alzheimer's disease and other Qpct-related disorders
DK2118101T3 (da) * 2007-03-09 2013-01-02 Probiodrug Ag IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
JP5675344B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのニトロビニルジアミン誘導体
US8772508B2 (en) * 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9656991B2 (en) * 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9512082B2 (en) * 2007-04-18 2016-12-06 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2008128982A1 (en) * 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
ES2474693T3 (es) * 2007-04-18 2014-07-09 Probiodrug Ag Derivados de ciano-guanidina como inhibidores de glutaminil ciclasa
EP2142536B1 (en) * 2007-04-20 2015-10-21 Probiodrug AG Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
CN101802000A (zh) * 2007-09-12 2010-08-11 前体生物药物股份公司 转基因小鼠
EP2238252B1 (en) * 2008-01-14 2013-07-31 Probiodrug AG Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
US20100028918A1 (en) * 2008-07-31 2010-02-04 Probiodrug Ag Glutaminyl cyclase as a diagnostic/prognostic indicator for neurodegenerative diseases
WO2010026209A1 (en) * 2008-09-04 2010-03-11 Probiodrug Ag Use of isoQC inhibitors
ES2599621T3 (es) * 2008-09-04 2017-02-02 Probiodrug Ag Nuevos inhibidores
CA2762404A1 (en) * 2009-05-19 2010-11-25 Probiodrug Ag Mouse models carrying a knock-out mutation of the qpctl-gene
SG182615A1 (en) * 2010-02-18 2012-08-30 Probiodrug Ag Methods of diagnosing inflammatory diseases by determining pyroglutamate-modified mcp-1 and screening methods for inhibitors of glutaminyl cyclase
EP2606129B1 (en) 2010-08-19 2015-03-25 Probiodrug AG Crystal structure of glutaminyl cyclase
JP2013541938A (ja) 2010-09-02 2013-11-21 プロビオドルグ エージー アイソｑｃ関連障害の治療のためのインビボスクリーニングモデル
JP6026425B2 (ja) 2010-11-02 2016-11-16 プロビオドルグ エージー イソグルタミニルシクラーゼの結晶構造
CA2879454A1 (en) 2012-07-19 2014-01-23 Drexel University Novel sigma receptor ligands and methods of modulating cellular protein homeostasis using same
WO2017079547A2 (en) * 2015-11-04 2017-05-11 The Scripps Research Institute Compositions and methods for treating cystic fibrosis
AU2018308191B2 (en) * 2017-07-24 2023-12-21 Scenic Immunology B.V. Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
GB201918108D0 (en) * 2019-12-10 2020-01-22 Vib Vzw Improved aminopeptiadases for single molecule peptide sequencing

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IT1183575B (it) 1985-05-08 1987-10-22 Eurand Spa Formulazione deodorando ad effetto modulante sulla trfaspirazione
DD293584A5 (de) 1990-03-23 1991-09-05 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6247293B1 (en) * 1998-11-03 2001-06-19 Klockner Bartelt, Inc. Modular packaging machine with web tension control
FR2796945B1 (fr) 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
AU2001231154A1 (en) 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
FR2808711B1 (fr) * 2000-05-10 2002-08-09 Poudres & Explosifs Ste Nale Procede de fabrication d'elements composites etain-tungstene de faible epaisseur
EP1388107A1 (en) * 2001-05-11 2004-02-11 Swisscom Mobile AG Method for transmitting an anonymous request from a consumer to a content or service provider through a telecommunication network
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
KR100474689B1 (ko) * 2001-08-30 2005-03-08 삼성전자주식회사 이동통신 시스템에서 소프트 핸드오프 도중의 전력제어 방법
WO2003045321A2 (en) * 2001-11-26 2003-06-05 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7677859B2 (en) 2002-07-22 2010-03-16 Brooks Automation, Inc. Substrate loading and uploading station with buffer
GB0220501D0 (en) * 2002-09-04 2002-10-09 Hall Geoffrey W Push 22
US20040098591A1 (en) * 2002-11-15 2004-05-20 Fahrny James W. Secure hardware device authentication method
US6851324B2 (en) * 2002-12-16 2005-02-08 Delphi Technologies, Inc. Non-contacting compliant torque sensor
JP4806628B2 (ja) * 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
CA2524009C (en) * 2003-05-05 2014-04-29 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US7381537B2 (en) * 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
US7192995B2 (en) * 2003-10-03 2007-03-20 Virginia Commonwealth University Homogenous compositions of polymers and crystalline solids or cross-linking agents and methods of making the same
WO2005039548A2 (en) * 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US7667044B2 (en) * 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2004290499C1 (en) * 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
WO2005049025A1 (en) * 2003-11-19 2005-06-02 Acrux Dds Pty Ltd Method and composition for treatment of cutaneous lesions
CA2554809C (en) * 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
WO2005108415A2 (en) * 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
MXPA06014651A (es) * 2004-07-01 2007-03-26 Micro Motion Inc Contrapesos de derivacion para eliminar el efecto de densidad en flujo.
US7663268B2 (en) * 2006-08-30 2010-02-16 The Regents of the University of Cailfornia Converters for high power applications
WO2008034891A2 (en) 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase
ES2468546T3 (es) 2006-11-09 2014-06-16 Probiodrug Ag Nuevos inhibidores de glutaminil ciclasa
EP2142536B1 (en) * 2007-04-20 2015-10-21 Probiodrug AG Aminopyrimidine derivatives as glutaminyl cyclase inhibitors

Also Published As

Publication number Publication date
EP2082041A2 (en) 2009-07-29
JP2010504088A (ja) 2010-02-12
EP2581449A2 (en) 2013-04-17
US20120183974A1 (en) 2012-07-19
US20100009337A1 (en) 2010-01-14
US8129160B2 (en) 2012-03-06
EP2581449A3 (en) 2013-07-31
EA016584B1 (ru) 2012-06-29
IL214820A (en) 2016-06-30
US20080249083A1 (en) 2008-10-09
EP2082041B1 (en) 2018-03-14
EP2581449B1 (en) 2016-09-14
WO2008034891A2 (en) 2008-03-27
HK1136603A1 (zh) 2010-07-02
KR20090059163A (ko) 2009-06-10
IL197090A (en) 2016-03-31
AU2007298929A1 (en) 2008-03-27
CA2663635A1 (en) 2008-03-27
IL214820A0 (en) 2011-09-27
US8647834B2 (en) 2014-02-11
WO2008034891A3 (en) 2008-05-08
BRPI0718507A2 (pt) 2013-11-12
MX2009003090A (es) 2009-04-02
NZ575727A (en) 2011-12-22
AU2007298929B2 (en) 2012-09-27
KR101432848B1 (ko) 2014-08-27
IL197090A0 (en) 2011-08-01
NZ590631A (en) 2011-12-22

Similar Documents

Publication Publication Date Title
EA200900404A1 (ru) Новые гены, родственные гену глутаминилциклазы
EA201201640A1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
Janzen et al. Unusual histone modifications in Trypanosoma brucei
BRPI0616824B8 (pt) peptídeo quimérico, seu uso, composição farmacêutica compreendendo o mesmo, e kit
CY1116175T1 (el) Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων καρδιαγγειακων νοσων
EA200800174A1 (ru) Резистентные к гербицидам растения подсолнечника, полинуклеотиды, кодирующие резистентные к гербицидам большие субъединицы белков ацетогидроксикислотной синтазы, и способы применения
NO20080067L (no) Polypeptider som har antimikrobeaktivitet og polynukleotider som koder for disse
ATE450547T1 (de) Eml4-alk-fusionsgen
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
BRPI0514396A2 (pt) polipeptìdeos dependentes de vitamina k modificada
DE602004021836D1 (de) Meg1-endospermspezifische promotoren und gene
CU23932B1 (es) Sales farmacéuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo y sus usos en terapia
MX2016017308A (es) Nuevo uso de inhibidores de peptido permeables a celulas de la ruta de transduccion de señal jnk para el tratamiento de varias enfermedades.
MX2014006399A (es) Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
DE602007004333D1 (de) Inhibitoren von akt (proteinkinase b)
NO20052956D0 (no) Defensinprotiner
EP2423684A3 (en) Differential expression profiling analysis of cell culture phenotypes and the uses thereof
NO20070640L (no) Forbedrede aprotininvananter
WO2015197194A3 (en) New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2004022756A3 (en) Protein kinases
ATE442382T1 (de) Ein die mam-domäne enthaltendes protein
DK1664102T3 (da) Isoleret photoprotein mtclytin, samt dets anvendelse
EA200801807A1 (ru) Новые оксидоредуктазы и их применение
JP2009524413A5 (ru)
AU2013263786B2 (en) Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU